Levodopa/Carbidopa/Entacapone Eg

Levodopa, carbidopa, and entacapone, the active ingredients in Levodopa/Carbidopa/Entacapone Eg, are antiparkinson agents presented as an oral tablet for oral use. They treat Parkinson's disease and associated motor fluctuations in adult patients, providing more consistent dopaminergic stimulation and reducing OFF periods.

GNH USA supplies Levodopa/Carbidopa/Entacapone Eg as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable global logistics. The company adheres to EU GMP standards and provides comprehensive documentation for import and distribution.

Levodopa/Carbidopa/Entacapone is used in the management of Parkinsonian disorders, targeting dopaminergic deficits. - Parkinson's disease: improves overall motor function and reduces rigidity. - Parkinson's disease motor fluctuations: decreases OFF time and prolongs ON time. - Parkinson's disease with wearing‑off phenomenon: enhances levodopa plasma half‑life for steadier symptom control. - Early-stage Parkinson's disease: provides initial dopaminergic support to delay progression of motor symptoms.

Adverse reactions may occur with Levodopa/Carbidopa/Entacapone therapy.

Common Side Effects: - Nausea: gastrointestinal upset common at treatment initiation. - Dizziness: may occur due to blood‑pressure changes. - Orthostatic hypotension: drop in blood pressure upon standing. - Insomnia: difficulty sleeping.

Serious or Rare Side Effects: - Severe hypotension: marked blood‑pressure decline requiring medical attention. - Hallucinations or psychosis: visual or auditory disturbances. - Dyskinesia: involuntary movements that may be disabling.

Before prescribing Levodopa/Carbidopa/Entacapone, clinicians should consider several safety measures. - Cardiovascular assessment: evaluate blood pressure and heart rate prior to therapy. - Psychiatric evaluation: monitor for depression, suicidal thoughts, or psychosis. - Renal function: adjust use in patients with severe renal impairment. - Hepatic function: use with caution in liver disease. - Concomitant MAO‑B inhibitors: avoid co‑administration due to risk of hypertensive crisis. - Store at ambient temperature: keep below 25°C in the original pack, protect from moisture.

Levodopa/Carbidopa/Entacapone may interact with several drug classes.

Major Interactions (Avoid): - Non‑selective MAO inhibitors: risk of hypertensive crisis. - Anticholinergic drugs: may reduce levodopa efficacy. - CNS depressants (e.g., barbiturates): may increase sedation.

Moderate Interactions (Monitor Closely): - Iron supplements: reduce levodopa absorption; separate dosing by at least 2 hours. - Antihypertensive agents: may enhance orthostatic hypotension. - SSRIs or SNRIs: potential for serotonin syndrome when combined with MAO‑B inhibitors.